What is Fortrea Holdings Inc.'s market cap?

Fortrea Holdings Inc. (FTRE) has a market capitalization of $1.8B and trades on NASDAQ.

What is Fortrea Holdings Inc.'s revenue and profitability?

Fortrea Holdings Inc. generated $2.7B in trailing twelve-month revenue with a net loss of $85.2M, representing a net margin of -3.2%. Gross margin stands at 19.3%, with free cash flow of -$10.6M. These figures are based on the Q2 2026 filing.

Who are Fortrea Holdings Inc.'s competitors?

Fortrea Holdings Inc.'s key competitors include Medpace Holdings, Inc., IQVIA Holdings Inc., ICON plc, and others. These companies compete in similar markets and product categories.

Who does Fortrea Holdings Inc. partner with?

Fortrea Holdings Inc.'s notable partners include Labcorp Holdings Inc., Arsenal Capital Partners.

What subsidiaries does Fortrea Holdings Inc. have?

Fortrea Holdings Inc.'s subsidiaries include Fortrea Inc..

Where is Fortrea Holdings Inc. headquartered?

Fortrea Holdings Inc. is headquartered in United States of America and employs approximately 16,000 people. It has been publicly traded since 2023.

Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc. is a leading global contract research organization (CRO) that provides comprehensive biopharmaceutical and medical device development solutions.

Market cap

$1.82B+224%

Revenue$2.7B-2.1%

Net income-$85.2M+91.7%

Free cash flow-$10.6M-104%

EPS (diluted)-$0.84+92.6%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q2 2026 report

July 29, 2026

Revenue$678.2MBeat by $30.7M EPS$0.23Beat by $0.05

Read the full report

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full

Revenue$678.2M-4.5%

Gross profit$139.2M+4.3%

Operating income$14.8M+104%

Net income-$13.2M+96.5%

EPS (diluted)-$0.14+96.6%

Balance sheet

See full

Cash & equivalents$168.6M+108%

Total debt$1.1B-10.0%

Total equity$524.2M-11.0%

Total assets$2.7B-4.2%

Cash flow

See full

Operating cash flow$28.9M—

CapEx$9.0M+20.0%

Free cash flow$19.9M—

Valuation & ratios

Valuation

See full

Market cap$1.82B+224%

Enterprise value$2.76B+55.2%

P/S0.7×+0.5×

Profitability

See full

Gross margin19.3%-0.4pp

Operating margin-0.4%-0.2pp

Net margin-3.2%-1.5pp

Returns & leverage

See full

Return on equity-15.3%-7.0pp

Debt / equity2.1×0.0×

Current ratio1×-0.1×

Competitors

By market cap

IQVIA$35.6B+5.9%

Medpace Holdings, Inc.$16.5B+29.2%

Icon$13.0B-11.7%

Charles River Laboratories$10.8B+22.9%

Fortrea Holdings Inc.$1.8B+192%

Fulcrum Therapeutics, Inc.$248.5M-41.0%

SPR

Spruce Biosciences, Inc. $115.6M—

Champions Oncology$84.2M-3.0%

By revenue growth

Medpace Holdings, Inc.+24.7%

IQVIA+8.2%

Charles River Laboratories+0.1%

Fortrea Holdings Inc.-2.1%

By net margin

Medpace Holdings, Inc.17.67%-1.1pp

IQVIA8.1%+0.2pp

Fortrea Holdings Inc.-3.18%+34.4pp

Charles River Laboratories-4.59%-11.1pp

Profile

Fortrea Holdings Inc. is a leading global contract research organization (CRO) that provides comprehensive biopharmaceutical and medical device development solutions. The company specializes in managing phase I through IV clinical trials, clinical pharmacology, and regulatory consulting for pharmaceutical and biotechnology customers. Its core value proposition lies in its ability to offer agile delivery models, including full-service and functional service provider structures, across approximately 100 countries.

Competitive position

A leading global CRO with a multi-decade track record and significant scale, operating in approximately 100 countries with specialized expertise in complex therapeutic areas like oncology and cell therapy.

GeographiesGlobal, United States, United Kingdom

Customer segmentsBiopharmaceutical Companies, Medical Device Developers, Life Science Innovators

Business modelProfessional Services, Outsourcing, Consulting

SuppliersTechnology vendors, Specialized bioanalytical equipment providers, Clinical trial software developers, Medical supply manufacturers

CustomersLarge-cap pharmaceutical firms, Emerging biotechnology startups, Medical device innovators, Academic research institutions

CountryUnited States of America

Listed2023

Employees16.0K

CEOAnshul Thakral

SectorHealthcare

IndustryBiotechnology

Websitefortrea.com

FilingsSEC EDGAR

Ask your AI about Fortrea Holdings Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Fortrea Holdings Inc.'s market cap?: Fortrea Holdings Inc. (FTRE) has a market capitalization of $1.8B and trades on NASDAQ.
What is Fortrea Holdings Inc.'s revenue and profitability?: Fortrea Holdings Inc. generated $2.7B in trailing twelve-month revenue with a net loss of $85.2M, representing a net margin of -3.2%. Gross margin stands at 19.3%, with free cash flow of -$10.6M. These figures are based on the Q2 2026 filing.
Who are Fortrea Holdings Inc.'s competitors?: Fortrea Holdings Inc.'s key competitors include Medpace Holdings, Inc., IQVIA Holdings Inc., ICON plc, and others. These companies compete in similar markets and product categories.
Who does Fortrea Holdings Inc. partner with?: Fortrea Holdings Inc.'s notable partners include Labcorp Holdings Inc., Arsenal Capital Partners.
What subsidiaries does Fortrea Holdings Inc. have?: Fortrea Holdings Inc.'s subsidiaries include Fortrea Inc..
Where is Fortrea Holdings Inc. headquartered?: Fortrea Holdings Inc. is headquartered in United States of America and employs approximately 16,000 people. It has been publicly traded since 2023.